PEDIATRIC PSYCHOPHARMACOLOGY
FAST FACTS

Daniel F. Connor, M.D.
Bruce M. Meltzer, M.D.

W. W. Norton & Company
New York • London
## Contents

<table>
<thead>
<tr>
<th>Part</th>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Preface</strong></td>
<td>xxv</td>
</tr>
<tr>
<td></td>
<td><strong>PART I: INTRODUCTION</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. Introduction to Pediatric Psychopharmacology</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>A Brief History of the Field</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Epidemiological Trends in Pediatric Psychopharmacology</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>Prescribing Algorithms</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Psychiatric Medication Use in Preschool Children</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Regulatory Issues in Pediatric Psychopharmacology</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>Off-Label Prescribing</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td><em>The Regulatory Process of Drug Development</em></td>
<td>9</td>
</tr>
<tr>
<td></td>
<td><em>FDA Initiatives to Promote Pediatric Drug Development</em></td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>Ethical Issues in Pediatric Psychopharmacology</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>Developmental Pharmacology, Neurobiology, and Pediatric Psychopharmacology</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>2. Basic Pharmacology</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>Pharmacokinetics</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>Absorption</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>Key Concepts</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>Distribution</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>Elimination</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>Elimination Kinetics</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>Elimination Half-Life</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>Pediatric Variations in Pharmacokinetics</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>Cytochrome P450 Enzymes</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>Summary</td>
<td>22</td>
</tr>
<tr>
<td></td>
<td>3. General Principles of Treatment</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>Psychiatric Evaluation in Pediatric Psychopharmacology</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>Sources of Information</td>
<td>24</td>
</tr>
</tbody>
</table>
PART II: THE MEDICATIONS

4. Stimulants
   Stimulant Drug Schedules
   Indications
   Efficacy in ADHD
   Efficacy in Narcolepsy
   Pharmacoepidemiology
   Currently Available Stimulants
   Pharmacology
      Pharmacodynamics
      Pharmacokinetics
   Stimulant Formulations and Dose
      Clinical Efficacy
      FDA Approval
      Pemoline
   Stimulant Side Effects
      Stimulant Contraindications
   Stimulant Drug–Drug Interactions
   Management of Stimulant Overdose

5. Antidepressants
   Selective Serotonin Reuptake Inhibitors
      Fluoxetine
      Paroxetine
      Sertraline
      Citalopram
      Escitalopram
      Fluvoxamine
      SSRI Side Effects
      Drug–Drug Interactions
      Management of SSRI Overdose
   Atypical Antidepressants
      Bupropion
      Trazodone
Contents

Nefazodone 80
Mirtazapine 83
Serotonin Norepinephrine Reuptake Inhibiting Antidepressants 87
Venlafaxine 87
Duloxetine 90
Tricyclic Antidepressants 93
 Imipramine 93
 Desipramine 96
 Amitriptyline 98
 Nortriptyline 100
 Clomipramine 102
 TCA Drug–Drug Interactions 105
Monoamine Oxidase Inhibitors 107
Future Antidepressants in Pediatric Psychopharmacology? 108
 Meclobemide 108
 Reboxetine 108
Clinical Use of Antidepressants in Children and Adolescents 108
 Duration of Treatment 108
 Medical Monitoring for Increased Suicidality 109
 Lack of Response to Initial Antidepressant Treatment 109

6. Mood Stabilizers 111
Lithium 114
 Pharmacology 114
 Indications 115
 Dosing and Duration of Treatment 116
 Contraindications 119
 Side Effects 119
 Drug–Drug Interactions 119
 Management of Overdose 119
 Drug Interference with Diagnostic Laboratory Testing 121
Divalproex Sodium 122
 Pharmacology 122
 Indications 123
 Dosing and Duration of Treatment 123
 Contraindications 125
 Side Effects 126
 Drug–Drug Interactions 126
 Management of Overdose 127
 Drug Interference with Laboratory Testing 127
Carbamazepine 127
 Pharmacology 128
 Indications 129
 Dosing and Duration of Treatment 129
 Contraindications 132
 Side Effects 133
 Drug–Drug Interactions 133
Management Of Overdose
Drug Interference with Laboratory Testing

Lamotrigine
Pharmacology
Indications
Dosing and Duration of Treatment
Contraindications
Side Effects
Drug–Drug Interactions
Management of Overdose
Drug Interference with Laboratory Testing

Medical Management of Pediatric Patients Receiving Mood Stabilizers
Newer Anticonvulsants with Potential Utility as Mood-Stabilizing Agents
Gabapentin
Oxcarbazepine
Tiagabine
Topiramate

7. Antipsychotics
Second-Generation Antipsychotics
Pharmacology
Indications
Choosing A Second-Generation Antipsychotic
Common Side Effects
Drug–Drug Interactions
Management of Overdose
First-Generation Antipsychotics
Chlorpromazine
Thioridazine Hydrochloride
Haloperidol
Pimozide
Fluphenazine Hydrochloride
Molindone Hydrochloride
Trifluoperazine Hydrochloride
Side Effects
Management of Side Effects

8. Drugs to Treat Extrapyramidal Symptoms and Syndromes
Anticholinergics
Pharmacology
Indications
Pertinent Studies
Choosing an Anticholinergic for EPS
Contraindications
Side Effects
Drug–Drug Interactions 175
Management of Overdose 176
Drug Interference with Laboratory Testing 177

Amantadine Hydrochloride
Pharmacology 177
Indications 178
Pertinent Studies 178
Dosing and Duration of Treatment 178
Contraindications 179
Side Effects 179
Management of Side Effects 179
Drug–Drug Interactions 180
Drug Interference with Laboratory Testing 180

Bromocriptine and Pergolide
Pharmacology 180
Dosing 181
Side Effects 181

Vitamin E
Pharmacology 181
Dosing 182
Contraindications 182
Side Effects 182

9. Anxiolytics 183
Benzodiazepines
Pharmacology 183
Indications 188
Choosing a Benzodiazepine 189
Dosing and Duration of Treatment 191
Contraindications 195
Side Effects 195
Drug–Drug Interactions 196
Management of Overdose 196
Drug Interference with Laboratory Testing 197

Buspirone
Pharmacology 198
Indications 199
Dosing and Duration of Treatment 200
Contraindications 202
Side Effects 202
Drug–Drug Interactions 202
Management of Overdose 203
Drug Interference with Laboratory Testing 203

Other Drugs
Antihistamines 203
Chloral Hydrate 208
Novel Benzodiazepine Receptor Agonists 209
10. **Adrenergic Agents**

**Clonidine**
- Pharmacology
- Indications
- Dosing and Duration of Treatment
- Contraindications
- Side Effects
- Drug–Drug Interactions
- Management of Overdose
- Drug Interference with Laboratory Testing

**Guanfacine**
- Pharmacology
- Indications
- Dosing and Duration of Treatment
- Contraindications
- Side Effects
- Drug–Drug Interactions
- Management of Overdose
- Drug Interference with Laboratory Testing

**Beta-Blockers**
- Pharmacology
- Indications
- Dosing and Duration of Treatment
- Contraindications
- Side Effects
- Drug–Drug Interactions
- Management of Overdose
- Drug Interference with Laboratory Testing

11. **Other Medications**

**Atomoxetine**
- Pharmacology
- Indications
- Dosing and Duration of Treatment
- Contraindications
- Side Effects
- Drug–Drug Interactions
- Management of Overdose
- Drug Interference with Laboratory Testing

**Modafinil**
- Pharmacology
- Indications
- Dosing and Duration of Treatment
- Contraindications
- Side Effects
- Drug–Drug Interactions
- Management of Overdose
- Drug Interference with Laboratory Testing
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Desmopressin Acetate</td>
<td>243</td>
</tr>
<tr>
<td>Pharmacology</td>
<td>243</td>
</tr>
<tr>
<td>Indications</td>
<td>243</td>
</tr>
<tr>
<td>Dosing and Duration of Treatment</td>
<td>244</td>
</tr>
<tr>
<td>Contraindications</td>
<td>244</td>
</tr>
<tr>
<td>Side Effects</td>
<td>244</td>
</tr>
<tr>
<td>Drug–Drug Interactions</td>
<td>244</td>
</tr>
<tr>
<td>Management of Overdose</td>
<td>244</td>
</tr>
<tr>
<td>Drug Interference with Laboratory Testing</td>
<td>245</td>
</tr>
<tr>
<td>Oxybutynin</td>
<td>245</td>
</tr>
<tr>
<td>Pharmacology</td>
<td>245</td>
</tr>
<tr>
<td>Indications</td>
<td>245</td>
</tr>
<tr>
<td>Dosing and Duration of Treatment</td>
<td>246</td>
</tr>
<tr>
<td>Side Effects</td>
<td>246</td>
</tr>
<tr>
<td>Drug–Drug Interactions</td>
<td>246</td>
</tr>
<tr>
<td>Management of Overdose</td>
<td>247</td>
</tr>
<tr>
<td>Drug Interference with Laboratory Testing</td>
<td>247</td>
</tr>
<tr>
<td>Tolterodine</td>
<td>247</td>
</tr>
<tr>
<td>Pharmacology</td>
<td>247</td>
</tr>
<tr>
<td>Indications</td>
<td>248</td>
</tr>
<tr>
<td>Dosing and Duration of Treatment</td>
<td>248</td>
</tr>
<tr>
<td>Contraindications</td>
<td>248</td>
</tr>
<tr>
<td>Side Effects</td>
<td>248</td>
</tr>
<tr>
<td>Drug–Drug Interactions</td>
<td>249</td>
</tr>
<tr>
<td>Management of Overdose</td>
<td>249</td>
</tr>
<tr>
<td>Drug Interference with Laboratory Testing</td>
<td>249</td>
</tr>
<tr>
<td>Naltrexone</td>
<td>249</td>
</tr>
<tr>
<td>Pharmacology</td>
<td>250</td>
</tr>
<tr>
<td>Indications</td>
<td>250</td>
</tr>
<tr>
<td>Contraindications</td>
<td>251</td>
</tr>
<tr>
<td>Side Effects</td>
<td>251</td>
</tr>
<tr>
<td>Drug–Drug Interactions</td>
<td>253</td>
</tr>
<tr>
<td>Management of Overdose</td>
<td>253</td>
</tr>
<tr>
<td>12. Herbal and Alternative Medicines</td>
<td>255</td>
</tr>
<tr>
<td>Regulatory Issues</td>
<td>255</td>
</tr>
<tr>
<td>St. John's Wort</td>
<td>256</td>
</tr>
<tr>
<td>Pharmacology</td>
<td>256</td>
</tr>
<tr>
<td>Indications</td>
<td>257</td>
</tr>
<tr>
<td>Dosing and Duration of Treatment</td>
<td>257</td>
</tr>
<tr>
<td>Contraindications</td>
<td>258</td>
</tr>
<tr>
<td>Side Effects</td>
<td>258</td>
</tr>
<tr>
<td>Drug–Drug Interactions</td>
<td>259</td>
</tr>
<tr>
<td>Melatonin</td>
<td>259</td>
</tr>
<tr>
<td>Pharmacology</td>
<td>260</td>
</tr>
<tr>
<td>Indications</td>
<td>260</td>
</tr>
<tr>
<td>Dosing and Duration of Treatment</td>
<td>262</td>
</tr>
<tr>
<td>Contraindications</td>
<td>262</td>
</tr>
<tr>
<td>Melatonin</td>
<td>259</td>
</tr>
<tr>
<td>Pharmacology</td>
<td>260</td>
</tr>
<tr>
<td>Indications</td>
<td>260</td>
</tr>
<tr>
<td>Dosing and Duration of Treatment</td>
<td>262</td>
</tr>
<tr>
<td>Contraindications</td>
<td>262</td>
</tr>
</tbody>
</table>
Side Effects 262
Drug–Drug Interactions 262
Essential Fatty Acids 262
Secretin 263
Kava 263
Valerian 264
Conclusions 264

13. Electroconvulsive Therapy in Adolescents 265
Evidence of Effectiveness 266
Indications for ECT in Adolescents 267
Predictors of Response 268
Contraindications 268
Assessment of the Adolescent for ECT 268
Description and Administration 269
Adverse Effects 270
Legal Considerations 271
Informed Consent and Assent 272
Transcranial Magnetic Stimulation 272

PART III: THE DISORDERS AND THEIR TREATMENT

14. Attention-Deficit/Hyperactivity Disorder 275
Diagnostic Features 275
Prevalence 276
Etiology 277
Course of Illness 277
Comorbidity in ADHD 278
Assessment 279
Treatment Options 279
Psychosocial Interventions 279
Medication Interventions 281
Stimulants in ADHD 282
Indications 282
Choosing A Stimulant 284
Stimulant Treatment 284
Stimulant Nonresponders 286
Stimulant Side Effects 287
Nonstimulants in ADHD 289
Bupropion 292
Atomoxetine 292
Clonidine and Guanfacine 293
Modafinil 295
Tricyclic Antidepressants 295
Clinical Management of ADHD with Comorbid Psychiatric Disorders 295
Oppositional Defiant Disorder/Conduct Disorder 296
15. Tic Disorders and Tourette's Disorder
Diagnostic Features 303
Prevalence 303
Comorbidity 305
Course of Illness and Outcome 306
Assessment 306
Treatment 307
Pharmacotherapy 307
  Typical Neuroleptics 309
  Atypical Antipsychotics 311
  Pergolide 312
  Alpha-Adrenergic Agonists: Clonidine and Guanfacine 312
  Other Tic-Suppressing Agents 313
Pharmacological Treatment of ADHD in Patients with
  Tic Disorders or Tourette's disorder 313
Stimulants and Tic Disorder 315
  Nonstimulant Medication Alternatives for Combined
  ADHD and Tic Disorder 315
Combined Pharmacotherapy 317
Pharmacological Treatment of OCD in Patients with
  Tic Disorders or Tourette's disorder 317
Pediatric Autoimmune Neuropsychiatric Disorders
  Associated with Streptococcas 318

16. Conduct Disorder, Oppositional Defiant Disorder, and Impulsive Aggression
  Oppositional Defiant Disorder 320
    Prevalence 320
    Etiology 320
    Course of Illness 321
  Conduct Disorder 321
    Prevalence 322
    Etiology 323
    Course of Illness 323
Comorbidity in ODD and CD 324
Psychopharmacological Treatment of ODD and CD
Impulsive Aggression
Treatment of Excessive, Maladaptive Aggression
   Psychosocial Treatments
   Educational Interventions
   Psychopharmacological Treatments
Measuring Treatment Response
A Clinical Approach to the Aggressive Child or Adolescent

17. Mood Disorders
   Depressive Disorders
      Diagnostic Features and Subtypes of Mood Disorders
      Prevalence
      Comorbidity
      Course of Illness
      Assessment
      Cultural Factors Affecting Assessment
      Treatment of Depression
   Bipolar Disorders
      Description and Diagnostic Features
      Comorbidity
      Prevalence
      Course of Illness
      Assessment
   Treatment of Pediatric Bipolar Illness
      Psychosocial Therapies
      Psychopharmacology
      Choosing a Medication
      Duration of Treatment
   Pediatric Bipolar Illness Medication Treatment Algorithm
      Acute Treatment
      Maintenance Treatment
      Treatment of Comorbid ADHD

18. Psychotic Disorders
   Developmental Considerations
   Prevalence
   Comorbidity
   Assessment
   Early-Onset Schizophrenia
      Prevalence
      Course and Prognosis
      Assessment
   Treatment Options
      Psychopharmacological Treatments
      Psychosocial Treatments
19. Extrapyramidal Syndromes and Central Serotonin Syndrome
   Acute Dystonic Reactions 401
   Parkinsonism 402
   Akathisia 403
   Tardive and Other Neuroleptic-Related Dyskinesias 403
     Assessment of Neuroleptic-Induced Dyskinesias 405
     Etiology of Neuroleptic-Induced Dyskinesias 405
     Treatment of Neuroleptic-Induced Dyskinesias 406
   Neuroleptic Malignant Syndrome 407
   Central Serotonin Syndrome 408

20. Anxiety Disorders
   Prevalence and Epidemiology 411
   Comorbidity 412
   Assessment 413
   Separation Anxiety Disorder 414
   Panic Disorder With and Without Agoraphobia 416
   Generalized Anxiety Disorder 417
   Social Phobia 418
   Treatment Options for Anxiety Disorders 419
     Psychosocial Therapies 420
     Psychopharmacology in Pediatric Anxiety Disorders 420

21. Obsessive–Compulsive Disorder
   Prevalence 427
   Comorbidity 428
   Course of Illness and outcome 429
   Assessment 429
   Treatment 430
     Cognitive-Behavioral Therapy 432
     Psychopharmacology 432
   Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcas 438

22. Posttraumatic Stress Disorder
   Prevalence 439
   Comorbidity 440
   Course of Illness and Outcome 442
   Assessment 443
   Treatment Options 443
     Psychosocial Interventions 445
     Psychopharmacology 446

23. Mental Retardation, Autism, and Other Pervasive Developmental Disorders
   Mental Retardation 455
     Diagnostic Features 455
24. **Eating Disorders**

**Diagnostic Criteria**
- Anorexia Nervosa
- Bulimia Nervosa
- Binge Eating Disorder

**Prevalence**
- Anorexia Nervosa
- Bulimia Nervosa
- Binge Eating Disorder

**Comorbidity**

**Assessment**

**Multidisciplinary Treatment**
- Anorexia Nervosa
- Bulimia Nervosa

**Psychopharmacological Treatment**
- Adjunctive Medications in Anorexia Nervosa
- Adjunctive Medications in Bulimia Nervosa

25. **Sleep Disorders**

**Normal Sleep Architecture**

**Difficulties Falling Asleep or Night Waking**

**Unusual Arousal Events During Sleep (Parasomnias)**
- Night Terrors, Sleepwalking, and Sleep Talking
- Nightmares
- Nocturnal Enuresis

**Excessive Daytime Sleepiness**
- Disturbed Nocturnal Sleep
- Sleep-Disordered Breathing and Sleep Apnea
- Narcolepsy

**Sleep Problems Associated with Psychiatric Conditions**
- Attention-Deficit/Hyperactivity Disorder
- Depression
- Bipolar Disorder
Contents

Anxiety Disorders 501
Psychotic Disorders 502
Developmental Delay 502
Sleep Problems Associated with Medical and Neurological Disorders 502

26. Other Important Topics in Pediatric Psychopharmacology 503

Combined Pharmacotherapy 503
Reasons for Rational Combined Pharmacotherapy 503
Prevalence of Combined Pharmacotherapy 504
Controlled Studies of Combined Pharmacotherapy 504
Combined Pharmacotherapy in the Clinical Setting 505

Psychopharmacology and the Suicidal Patient 507
Epidemiology 507
Etiology 507
Assessment of the Suicidal Child or Adolescent 508
Treatment of the Suicidal Child or Adolescent 510

An Approach to Pediatric Psychopharmacology in Conflicted Family Situations 511
Psychopharmacology and The Substance-Abusing Youngster 512
General Treatment Considerations in Youth with Psychiatric Disorder and SUDs 512

APPENDICES 515

Appendix 1: Pediatric Psychopharmacology
Summary Table: Evidence of Efficacy by Drug and Disorder in Children and Adolescents < 18 Years Old 517

Appendix 2: Pharmacodynamics of Psychiatric Medications Commonly Used in Children and Adolescents 521
Pharmacodynamics of Antidepressants 522
Pharmacodynamics of Atypical Antipsychotics 522
Pharmacodynamics of Anticonvulsants 522
Pharmacodynamics of Stimulants 526

Appendix 3: Pediatric Psychopharmacology and the Cardiovascular System 529
The ECG 529
Reading the ECG 530
ECG Parameters 531
Psychiatric Medications and the ECG 532
Pulse and Blood Pressure 533

Appendix 4: Practical Tools for the Clinical Child and Adolescent Psychopharmacologist 537
Growth Curves: Boys 538
Growth Curves: Girls 539
Parent’s Questionnaire 540
Patient Medication Log 546
Medication Side Effects Rating Scales 548
Antipsychotic Side Effects Profile 550
Atomoxetine Side Effects Profile 551
Antidepressant Side Effects Profile 553
Benzodiazepine Side Effects Profile 554
Buspirone Side Effects Profile 555
Carbamazepine Side Effects Profile 556
Clonidine/Guanfacine Side Effects Profile 557
Lamotrigine Side Effects Profile 558
Lithium Side Effects Profile 559
Monoamine Oxidase Inhibitor Side Effects Profile 560
Modafinil Side Effects Profile 562
Oxcarbazepine Side Effects Profile 563
Stimulant Side Effects Profile 564
Topiramate Side Effects Profile 565
Valproic Acid/Divalproex Side Effects Profile 566
Abnormal Involuntary Movement Scale (AIMS) 568
Clinical Global Impressions (CGI) 573
Global Assessment Children's Scale (CGAS) 574
Disorder Rating Scales 576
Brief Psychiatric Rating Scale for Children (BPRS-C) 578
Pediatric Symptom Checklist (PSC) 580
The SNAP-IV Teacher and Parent Rating Scale 585
Abbreviated Parent Questionnaire 586
Children's Depression Rating Scale—Revised (CDRS-R) 596
Yale–Brown Obsessive Compulsive Scale (Y-BOCS) 599
Children's Aggression Scale—Parent Version 601
Overt Aggression Scale 602
The Nisonger Child Behavior Rating Form: Parent Version 605
The Nisonger Child Behavior Rating Form: Teacher Version 609
Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) 609

Appendix 5: Parent Support Resources 611
General Mental Health Resources for Children and Adolescents 611
Attention-Deficit/Hyperactivity Disorder 612
Bipolar Disorder 612
Depression 612
Independent Herbal and Alternative Medication Internet Sites 612
Learning Disabilities 612
Mental Retardation 613
Obsessive–Compulsive Disorder 613
Tic Disorders and Tourette's Disorder 613

Bibliography 615
Introduction to Pediatric Psychopharmacology 615
Basic Pharmacology 616
<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>General Principles of Treatment</td>
<td>617</td>
</tr>
<tr>
<td>Stimulants</td>
<td>617</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>619</td>
</tr>
<tr>
<td>Mood Stabilizers</td>
<td>622</td>
</tr>
<tr>
<td>Antipsychotics</td>
<td>625</td>
</tr>
<tr>
<td>Drugs to Treat Extrapyramidal Symptoms and Syndromes</td>
<td>626</td>
</tr>
<tr>
<td>Anxiolytics</td>
<td>628</td>
</tr>
<tr>
<td>Adrenergic Agents</td>
<td>630</td>
</tr>
<tr>
<td>Other Medications</td>
<td>631</td>
</tr>
<tr>
<td>Herbal and Alternative Medicines</td>
<td>633</td>
</tr>
<tr>
<td>Electroconvulsive Therapy in Adolescents</td>
<td>635</td>
</tr>
<tr>
<td>Attention-Deficit Hyperactivity Disorder</td>
<td>636</td>
</tr>
<tr>
<td>Tic Disorders and Tourette's disorder</td>
<td>639</td>
</tr>
<tr>
<td>Conduct Disorder, Oppositional Defiant Disorder, and Impulsive Aggression</td>
<td>642</td>
</tr>
<tr>
<td>Mood Disorders</td>
<td>644</td>
</tr>
<tr>
<td>Psychotic Disorders</td>
<td>651</td>
</tr>
<tr>
<td>Extrapyramidal Syndromes and Central Serotonin Syndrome</td>
<td>653</td>
</tr>
<tr>
<td>Anxiety Disorders</td>
<td>655</td>
</tr>
<tr>
<td>Obsessive–Compulsive Disorder</td>
<td>657</td>
</tr>
<tr>
<td>Posttraumatic Stress Disorder</td>
<td>659</td>
</tr>
<tr>
<td>Mental Retardation, Autism, and other Pervasive Developmental Disorders</td>
<td>660</td>
</tr>
<tr>
<td>Eating Disorders</td>
<td>664</td>
</tr>
<tr>
<td>Sleep Disorders</td>
<td>666</td>
</tr>
<tr>
<td>Other Important Topics in Pediatric Psychopharmacology</td>
<td>667</td>
</tr>
<tr>
<td>Pediatric Psychopharmacology and the Cardiovascular System</td>
<td>669</td>
</tr>
</tbody>
</table>

Index 671